Klinik für Innere Medizin II, Universitätsklinikum Ulm, Albert Einstein Allee 23, 89081, Ulm, Germany.
Clin Res Cardiol. 2022 Oct;111(10):1121-1129. doi: 10.1007/s00392-022-02032-z. Epub 2022 May 23.
During the COVID-19 pandemic, in anticipation of a demand surge for high-care hospital beds, many hospitals postponed non-emergency interventions of cardiac patients.
The aim of this study was to assess the outcomes of cardiac patients whose non-emergency interventions had been deferred during the COVID-19 pandemic.
Patients whose non-emergency cardiac intervention had been cancelled between March 19th and April 30th, 2020 were included (study group). All patients were considered as deferrable according to current recommendations. Patients' outcomes after 12 months were compared to a seasonal control group who underwent non-emergency interventions in 2019 as scheduled. The primary endpoint was a composite of emergency cardiovascular hospitalization and death. Secondary endpoints were levels of symptoms and cardiac biomarkers.
Outcomes of 193 consecutive patients in the study group were assessed and compared to 216 controls. The primary endpoint occurred significantly more often in the study group (HR 2.42, 95%CI 1.63-3.61, p < 0.001). This was driven by an increase in hospitalizations. Subgroup analyses showed that especially patients with a deferred transcatheter heart valve intervention experienced early emergency hospitalization (HR 9.55, 95%CI 3.70-24.62, p < 0.001). These findings were accompanied by more pronounced symptoms and higher biomarker levels.
Deferral of non-emergency cardiac interventions to meet the higher demand for hospital beds during the COVID-19 crisis is associated with early emergency cardiovascular hospitalizations. Patients suffering from valvular heart disease especially constitute a vulnerable group. Consequently, our results suggest that current recommendations on the management of cardiovascular disease during the COVID-19 pandemic need revision.
在 COVID-19 大流行期间,许多医院为应对高需求的重症监护病床,推迟了心脏患者的非紧急干预。
本研究旨在评估 COVID-19 大流行期间非紧急心脏介入治疗被推迟的心脏患者的结局。
研究组纳入了 2020 年 3 月 19 日至 4 月 30 日期间取消非紧急心脏介入治疗的患者。所有患者根据当前建议均被认为是可延迟的。将 12 个月后的患者结局与 2019 年按计划进行非紧急干预的季节性对照组进行比较。主要终点是紧急心血管住院和死亡的复合终点。次要终点是症状和心脏生物标志物水平。
评估了研究组 193 例连续患者的结局,并与 216 例对照组进行了比较。研究组的主要终点发生率明显更高(HR 2.42,95%CI 1.63-3.61,p<0.001)。这是由于住院率增加所致。亚组分析表明,特别是接受经导管心脏瓣膜介入治疗延迟的患者,早期出现紧急住院(HR 9.55,95%CI 3.70-24.62,p<0.001)。这些发现伴随着更明显的症状和更高的生物标志物水平。
为满足 COVID-19 危机期间对病床的更高需求而推迟非紧急心脏介入治疗与早期紧急心血管住院有关。患有瓣膜性心脏病的患者尤其构成一个脆弱群体。因此,我们的结果表明,目前关于 COVID-19 大流行期间心血管疾病管理的建议需要修订。